Questions ?

There are two ways to find answers to your questions about the Diflucan® Partnership Program. Our "Frequently Asked Questions" section below addresses many common issues. For more technical questions or help establishing your program, please contact the program administrator directly.

Frequently Asked Questions

Diflucan®	Is Diflucan a cure for AIDS ? Is this a clinical trial ? Can anyone living with HIV/AIDS use Diflucan ? Will Diflucan be provided free for vaginal candidiasis (thrush) for HIV infected people ? Are there risks associated with the use of Diflucan® ?
The Diflucan® Partnership Program	Who is eligible ? What are the requirements ? What are the costs involved ? Who is involved ?
The Application Process	How do I apply ? Who is my contact ? Why are applications reviewed ? What are the review criteria ? How long does the review process take ? How will I know if I will receive the donation ? What happens when Pfizer approves my application ? Do I have to complete the entire application if I want to request a repeat donation ? What happens if my application requires clarifications ?
Privacy	What should I do if my information is private ? Who sees my information ?
Technical Issues	How do I read the documents in Adobe Acrobat® (PDF) format ? What if I have a problem with the forms ?

For more information, please see Welcome, Program, or News. If you do not find what you need, contact the program administrator and you will receive a personalized answer within five working days.

Diflucan®

• Is Diflucan® a cure for AIDS ?
  Diflucan® does not treat HIV/AIDS, but as an antifungal medicine it treats life-threatening opportunistic infections. In this program, Diflucan® is being donated to treat two fungal infections, Cryptococcal meningitis, and Esophageal candidiasis, with diagnosis made by a healthcare professional.

• Is this a clinical trial ?
  No. Diflucan® was approved in 1994 and has a proven record of safety and efficacy. The Diflucan® Partnership Program is a donation program.

• Can anyone living with HIV/AIDS use Diflucan® ?
  No. Only people who have been diagnosed with Cryptococcal meningitis or Esophageal candidiasis by a healthcare professional should be treated with Diflucan®.

• Will Diflucan® be provided free for vaginal candidiasis (thrush) for HIV-infected people ?
  Pfizer's donation program is only for the treatment of Cryptococcal meningitis and Esophageal candidiasis.

• Are there risks associated with the use of Diflucan® ?
  There are risks associated with use of any medicine. However, it is important to understand that the Diflucan ® Partnership Program is not a clinical trial. Diflucan has been approved and has been used for over ten years for the treatment of Cryptococcal meningitis and Esophageal candidiasis, and other indications. Please refer to the Diflucan ® prescribing information ( U.S.:  85K Adobe Acrobat document and South Africa : 38K Adobe Acrobat document ) and/or the summary below:

DIFLUCAN ® (FLUCONAZOLE) The product information provided in this site is intended only for non-United States residents. The products discussed herein may have different product labeling in different countries. Important Product Information Systemic In more than 4,000 patients, who received multiple doses of Diflucan ® , the most common adverse events were nausea (3.7%), headache (1.9%), skin rash (1.8%), vomiting (1.7%), abdominal pain (1.7%), and diarrhea (1.5%). Diflucan ® has been associated with rare cases of serious hepatic toxicity, including fatalities, primarily in patients with serious underlying medical conditions. Patients who develop abnormal liver function tests should be monitored for the development of more severe hepatic injury. Patients have rarely developed exfoliataive skin disorders during treatment with Diflucan ® . Coadministration of terfenadine is contraindicated in patients receiving Diflucan ® at multiple daily doses of 400 mg (equivalent to 12 mg/kg pediatric doses or higher) or higher. Coadministration of cisapride is contraindicated in patients receiving Diflucan® . Pediatric In 577 children, ages one day to seventeen years, who received Diflucan® , the most common treatment-related side effects were vomiting (5.4%), abdominal pain (2.8%), nausea (2.3%), and diarrhea (2.1%). For additional information, please see Diflucan ® prescribing information for the U.S. (38K Adobe Acrobat document) and for South Africa (85K Adobe Acrobat document).

The Diflucan® Partnership Program

• Who is eligible ?
  The Diflucan® Partnership Program is open to governments and non-governmental organizations in sub-Saharan Africa and in the 49 least developed countries with a greater than 1 percent HIV/AIDS prevalence, for HIV/AIDS patients suffering from Cryptococcal meningitis and/or Esophageal candidiasis.

• What are the requirements ?
  NGOs, charitable organizations, and other healthcare providers must obtain written agreement from the local government in order to receive the donated drug.

• What are the costs involved ?
  Pfizer will offer the Diflucan® for free and will cover the shipping costs up to the point of entry in the countries. All other costs will be the responsibility of the applicant including costs of the handling, taxes and duties, and distribution in the country.

  Diflucan must be provided free of charge to the patient.

• Who is involved ?
  Pfizer Inc is providing Diflucan®. Axios International is managing the application process. The International Dispensary Association (IDA) is responsible for shipping.

The Application Process

• How do I apply ?
  Applicants interested in applying to receive Diflucan® must complete a simple application. The application and the subsequent review process are designed to ensure that each application is assessed in a rapid and consistent manner. Axios assists Pfizer in reviewing all applications.

  If you have any issues that cannot be resolved through this Web site, please contact Axios International (See the next question for contact information.).

• Who is my contact ?
  Axios is assisting Pfizer to implement the program in all eligible countries. You can contact Axios via at the address and links below:

  Diflucan® Partnership Program
  Axios International
  Parklane Courts
  Plot 2, Park Lane, Kololo
  Behind Shell Lugogo
  P.O. Box 6924
  Kampala
  Tel: +256 31 264 475
  or +256 41 340 807
  Fax: +256 41 340 642
  axios@diflucanpartnership.org
  www.diflucanpartnership.org

• Why are applications reviewed ?
  Applications are reviewed to ensure that the donated Diflucan® will be used appropriately. It is important that both the donor (Pfizer) and the program receiving Diflucan® have a common understanding of who will benefit from Diflucan® and how it will be delivered and used.

• What are the review criteria ?
  Click here to read the review criteria.

• How long does the review process take ?
  Within five days of receiving your completed application, Axios will screen it to ensure it is ready for a detailed, technical review, and inform you if any additional information is needed.

If your application requires additional work before its technical review, you may re-edit your entire form online and re-submit it for initial screening. If your application does not require additional work, Axios' independent technical experts will carefully review your project according to the standard guidelines.

You will be notified if your application meets these guidelines and your Diflucan® donation will soon commence. If the reviewers conclude that the application does not meet the guidelines, Axios will work with you to clarify or amend your application. Once the proposal meets the requirements outlined in the standard guidelines, Axios will forward it to Pfizer and recommend that they consider it for approval.

• How will I know if I will receive the donation ?
  Each applying institution will receive an official letter to confirm that Pfizer has approved the donation of Diflucan®. Details concerning the quantity of drugs, timeline and shipping procedures will be defined with the responsible institution.

• What happens when Pfizer approves my application ?
  A shipping sheet will be sent to each approved program for completion. The applicant should provide the exact shipping address and any other relevant information necessary for sending the drug to the country. The freight forwarder or the International Dispensary Association may contact the person responsible for shipping to obtain information.

  The prescription and use of Diflucan® requires the product to be registered in the country of use. If Diflucan® is not registered, the applying institution needs to apply for a special import license for the donation from the local government.

  Pfizer will offer Diflucan® for free and will cover the shipping costs up to the point of entry in the countries. All other costs will be the responsibility of the applicant, including costs of handling, taxes and duties, and distribution in the country.

• Do I have to complete the entire application if I want to request a repeat donation ?
  No. Once an institution has received the first donation of Diflucan®, the request for resupply is straightforward. The institution will be asked to complete a form outlining the quantity of Diflucan requested and the justification for the amount. Pfizer retains the right to audit any facility.

• What happens if my application requires clarifications ?
  If the information provided in your application is not sufficient to give Axios a level of comfort to recommend your program, you will be requested to implement specific changes and revise it. Axios and Pfizer will be happy to assist you or put you in contact with relevant international institutions that can assist you.

Privacy

• What should I do if my information is private ?
  You are welcome to browse this Web site anonymously. We only require you sign in if you have a question or need help with your application.

• Who sees my information ?
  Only the application manager has access to your information and will keep it confidential. For more information, please see our privacy policy.

Technical issues

• How do I read the application and/or documents in Adobe Acrobat® (PDF) format ?
  You need the Acrobat Reader program. You can download it now free of charge from Adobe's Web Site.

• What if I have a problem with the forms ?
  If you have a technical problem with this web site or viewing the forms please send an email to DiflucanPartnership@AccessToTreatment.org , detailing your problem, the page, and the circumstances under which you encountered it.

 

Note: Pages will open in a new browser window.
External sites are not endorsed by the Diflucan ® Partnership Program.